Latest News and Press Releases
Want to stay updated on the latest news?
-
Focus on expanding the delivery of controlled-substances in a microneedle patch.Evaluating potential uses of a microneedle patch for infectious diseases.Strengthening capabilities in the manufacturing...
-
Leading U.S.-based CDMO to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.Expected FDA clinical and commercial supply in...
-
Achieving its second FDA orphan drug designation with ketamine.Building a proprietary ketamine-based product pipeline for rare and near-rare disorders in pain and inflammation.Seeking to enter Phase 2...
-
TORONTO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it...
-
TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that...
-
TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to announce...
-
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE:...
-
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
-
10 clinical sites selected to participate in the FDA Phase 2 clinical study evaluating ketamine for the treatment of Parkinson’s DiseaseInitiated investigational new drug (IND) application to proceed...
-
To provide an update on PharmaTher’s product pipeline and upcoming milestones on its FDA Phase 2 clinical studies and microneedle patch programs involving ketamine and psychedelics TORONTO, Sept. ...